Pressure on Patient Assistance Programs | Predictions for 2025
Predictions for 2025 by Tracy Baroni Allmon, J.D., vice president of Market Access and Policy at Magnolia Market Access.
With a new administration in place, many are focused on federal healthcare changes. But in 2025, the bigger challenges will come from how payers and states handle costs.
Allmon
Commercial health plans are moving away from copays toward coinsurance and stricter formularies, which means more patients will rely on manufacturer assistance programs. If the HELP Copays Act doesn’t pass in 2024, it’s unlikely we’ll see changes in 2025, leaving accumulator programs unchecked.
A few more states might pass laws to protect patients, but large employer plans are expected to keep expanding cost-saving programs like accumulators and maximizers. Manufacturers will need to do more to educate patients and doctors on how these programs work and how to advocate for access when care is delayed or denied.
These changes will put more pressure on patient assistance programs. Drug manufacturers should plan ahead with clear program rules to avoid problems later. Success in 2025 will depend on understanding the product payer mix, benefit designs and patients’ ability to pay — both at launch and throughout the product life cycle.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Medicaid Work Requirements Could Lead to Major Coverage Losses Across Expansion States in the U.S.
April 15th 2025The analysis from the Urban Institute breaks down projected coverage losses across the 40 Medicaid expansion states, where researchers based their estimates on previous work requirement rollouts in Arkansas and New Hampshire.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Analysis Finds Brukinsa May Provide Costs Savings Over Imbruvica in CLL
April 14th 2025In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.
Read More
